{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:36:59Z","timestamp":1783787819603,"version":"3.55.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"SI","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Skafit"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Silver fibre gloves transport heat from the palm to the fingers, possibly reducing the burden of RP in SSc patients. We aim to evaluate the clinical efficiency of this intervention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre, double-blind, randomized trial was performed, accounting for interindividual differences and external factors using a crossover design. Patients were randomized in two groups: group 1 wore 8% silver fibre gloves in period 1 and normal gloves in period 2 and group 2 vice versa. Each period lasted 6\u2009weeks. The primary outcome was the Raynaud Condition Score (RCS) over time (minimal clinical important difference 1.4), assessed three times per week using an online questionnaire. Secondary outcomes included vascular complications and Scleroderma-Health Assessment Questionnaire (SHAQ). Outcomes were evaluated before unblinding using linear mixed models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 85 SSc patients were included, with 76 completing the study. The mean RCS during 2\u2009weeks before the study (i.e. without gloves) was 6.4 (s.d. 1.6). Both with silver fibre gloves and normal gloves the mean RCS decreased to 3.9 (s.d. 2.3) with a similar course over time. There was no difference in mean RCS over time between the type of gloves [\u03b2\u2009=\u20090.067 (95% CI \u22120.006, 0.19)]. Of secondary outcomes, total SHAQ [\u03b2\u2009=\u20090.036 (95% CI 0.026, 0.046)] was slightly higher with silver fibre gloves, which is clinically irrelevant. Three patients developed new digital ulcers with normal gloves vs one patient with silver fibre gloves [odds ratio 3.2 (95% CI 0.32, 31.1)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Wearing gloves in SSc patients clearly decreases the RP burden. Our results do not support the hypothesis that increased heat transport of 8% silver fibre gloves is associated with less disease burden as measured in this study by the RCS compared with normal gloves.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial registration number<\/jats:title>\n                  <jats:p>Netherlands Trial register (https:\/\/www.trialregister.nl\/) NL7904<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac243","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:19:55Z","timestamp":1650050395000},"page":"SI74-SI81","source":"Crossref","is-referenced-by-count":9,"title":["The effect of silver fibre gloves on Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial"],"prefix":"10.1093","volume":"62","author":[{"given":"Sophie I E","family":"Liem","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M","family":"Hoekstra","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Bonte-Mineur","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Ziekenhuis , Rotterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Magro Checa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zuyderland Medical Center , Heerlen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schouffoer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Haga Ziekenhuis , The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia F","family":"Allaart","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W J","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeska K","family":"de Vries-Bouwstra","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"2023020607514926200_keac243-B1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023020607514926200_keac243-B2","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","article-title":"Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2023020607514926200_keac243-B3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2015.04.005","article-title":"Management of Raynaud phenomenon and digital ulcers in scleroderma","volume":"41","author":"Cappelli","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2023020607514926200_keac243-B4","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","article-title":"Review: evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023020607514926200_keac243-B5","first-page":"iii33","article-title":"Pathophysiology and clinical consequences of Raynaud\u2019s phenomenon related to systemic sclerosis","volume":"45(Suppl 3","author":"Sunderk\u00f6tter","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2023020607514926200_keac243-B6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kel038","article-title":"Iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol","volume":"45","author":"Milio","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2023020607514926200_keac243-B7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud\u2019s phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N Engl J Med"},{"key":"2023020607514926200_keac243-B8","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1093\/rheumatology\/keaa827","article-title":"Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants","volume":"60","author":"van Leeuwen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023020607514926200_keac243-B9","first-page":"D5630","article-title":"Sympathicotomie bij medicatieresistent fenomeen van Raynaud","volume":"165","author":"van Roon","year":"2021","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2023020607514926200_keac243-B10","year":"2019"},{"key":"2023020607514926200_keac243-B11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1128\/AAC.31.1.93","article-title":"Silver-coated nylon fiber as an antibacterial agent","volume":"31","author":"MacKeen","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020607514926200_keac243-B12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/nl5036572","article-title":"Personal thermal management by metallic nanowire-coated textile","volume":"15","author":"Hsu","year":"2015","journal-title":"Nano Lett"},{"key":"2023020607514926200_keac243-B13","first-page":"65","article-title":"Effect of silver-threads-containing compression stockings on the cutaneous microcirculation: a double-blind, randomized cross-over study","volume":"36","author":"Jaccard","year":"2007","journal-title":"Clin Hemorheol Microcirc"},{"key":"2023020607514926200_keac243-B14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1759720X17740074","article-title":"Evidence-based management of Raynaud\u2019s phenomenon","volume":"9","author":"Herrick","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2023020607514926200_keac243-B15","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/rheumatology\/keab537","article-title":"Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud\u2019s phenomenon, and digital ulcers in patients with systemic sclerosis","volume":"61","author":"St\u00f6cker","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023020607514926200_keac243-B16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2023020607514926200_keac243-B17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023020607514926200_keac243-B18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2009.107706","article-title":"The minimally important difference and patient acceptable symptom state for the Raynaud\u2019s condition score in patients with Raynaud\u2019s phenomenon in a large randomised controlled clinical trial","volume":"69","author":"Khanna","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023020607514926200_keac243-B19","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023020607514926200_keac243-B20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3899\/jrheum.080479","article-title":"The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials","volume":"36","author":"Pope","year":"2009","journal-title":"J Rheumatol"},{"key":"2023020607514926200_keac243-B21","doi-asserted-by":"crossref","first-page":"102142","DOI":"10.1016\/j.nano.2019.102142","article-title":"Silver-based antibacterial strategies for healthcare-associated infections: processes, challenges, and regulations. An integrated review","volume":"24","author":"Bonilla-Gameros","year":"2020","journal-title":"Nanomedicine"},{"key":"2023020607514926200_keac243-B22","doi-asserted-by":"crossref","first-page":"100684","DOI":"10.1016\/j.conctc.2020.100684","article-title":"Intention-to-treat analysis when only a baseline value is available","volume":"20","author":"Twisk","year":"2020","journal-title":"Contemp Clin Trials Commun"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac243\/43638263\/keac243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI\/SI74\/49085124\/keac243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI\/SI74\/49085124\/keac243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T07:52:32Z","timestamp":1675669952000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/SI\/SI74\/6571140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":22,"journal-issue":{"issue":"SI","published-online":{"date-parts":[[2022,4,20]]},"published-print":{"date-parts":[[2023,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac243","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,4,20]]}}}